Leukemia, Bladder Cancer Drug Markets Expected to Soar
The market for acute lymphocytic leukemia and bladder cancer drug therapies is expected to soar over the next few years, thanks in part to new and innovative medications.
The market for acute lymphocytic leukemia (ALL) and bladder cancer drug therapies is expected to soar over the next few years, thanks in part to new and innovative medications.
The ALL market, which has realized “explosive” growth since 2015, will skyrocket to $2.26 billion in 2029, according to a new report from data and analytics firm GlobalData.1
The growth represents a moderate compound annual growth rate (CAGR) of 4.4% across 8 major markets—the US, France, Germany, Italy, Spain, the UK, Japan, and China—according to a press release about the report.1
The increase can be attributed to the use of already successful treatments in more patient populations and by the regulatory approval of late-stage pipeline drugs, GlobalData said in the news release.1 The already successful treatments that will be expanded include: tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy (Kymriah; Novartis), blinatumomab (Blincyto; Amgen), and inotuzumab ozogamicin (Besponsa; Pfizer).
“ALL presents some of the most interesting market dynamics in oncology. Despite being a rare disease, it has a market value on par with more prevalent diseases such as acute myeloid leukemia,” said Sakis Paliouras, PhD, oncology analyst at GlobalData. “This is due to all lines of therapy consisting of high-priced agents such as Kymriah, Blincyto, and Besponsa in the relapsed/refractory setting, some of which involve multiple years of treatment, such as Servier’s Oncaspar and Asparlas in the front-line setting.”
In addition, special regulatory designations—primarily in the US—have allowed pharmaceutical companies to pursue innovative efforts in ALL, “despite the relatively smaller pay-out compared to other, more lucrative indications,” Paliouras said.
GlobalData forecasts 5 novel agents will enter the market from now through 2029, including Gilead’s Tecartus and Autolus Therapeutics' AUTO1.
“If AUTO1 delivers on its promise to move CAR-T cell infusions to the outpatient setting, it will gain a significant competitive advantage over Tecartus and Kymriah,” Paliouras said. “CAR-T cells are forecast to consolidate their market share through label expansions and introduction in other markets, and are expected to become the leading class of therapy by 2029.”
Meanwhile, GlobalData expects the bladder cancer therapeutics market to surge from $670 million in 2018 to nearly $5.6 billion in 2029, representing a CAGR of 23.6%.
Key opinion leaders interviewed by GlobalData believe that therapies such as enfortumab vedotin-ejfv (Padcev; Astellas Pharma Inc and Seattle Genetics) and its combination with pembrolizumab (Keytruda; Merck), sacituzumab govitecan (Trodelvy; Immunomedics), and bempegaldesleukin (NKTR-214; Nektar Therapeutics) in combination with nivolumab (Opdivo; Bristol Myers Squibb), carry tremendous potential to benefit muscle invasive, locally advanced and metastatic bladder cancer patients, GlobalData said in a news release.2
“The treatment paradigm for bladder cancer is expected to transform rapidly due to recently approved novel targeted therapies such as Padcev and Balversa,” said Ufuk Ezer, MSc, oncology and hematology analyst at GlobalData.
Anticipated approvals of the gene therapy instiladrin, targeted therapy vicinium, and novel immunotherapies such as CG0070 and N-803 are expected to benefit patients with superficial or non-muscle invasive bladder cancer, according to Ezer. “Nonetheless, for these patients, Bacillus Calmette-Guerin (BCG) is expected to remain as an important treatment option despite the introduction of new therapies,” Ezer said.
References:
1. Acute lymphocytic leukemia market is forecast to reach $2.26bn by 2029. News release. GlobalData; November 30, 2020. Accessed December 8, 2020. https://www.globaldata.com/acute-lymphocytic-leukemia-market-forecast-reach-2-26bn-2029/
2. Bladder cancer therapeutics market projected to exceed $5.5bn by 2028. News release. GlobalData; December 2, 2020. Accessed December 8, 2020. https://www.globaldata.com/bladder-cancer-therapeutics-market-projected-exceed-5-5bn-2028/
